vonoprazan
vonoprazan: developed by 1 company · 8 clinical trials tracked.
vonoprazan evidence translation
What we can confirm
8 tracked trials
What it means
What to watch
Prepared research question
How could vonoprazan → PHAT affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence3 indications · 2 study sponsors
Related indications
Development Pipeline (1)
| Company | Phase |
|---|---|
| Phathom Pharmaceuticals, Inc. (PHAT) Erosive Esophagitis; Gastroesophageal Reflux; Eosinophilic E… | Phase 3 |
Clinical Trials (8)
A Phase 3, Randomized, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of Vonoprazan 10 mg Compared to Placebo for Relief of Episodic Heartburn in Subjects With Symptomatic Non-Erosive Gastroesophageal Reflux Disease Through 24 Weeks
Primary endpoint: Percentage of Treated Heartburn Episodes Achieving Complete Relief at 2 Hours and Sustained Relief for 24 Hours up to Week 12
A Phase 2, Randomized, Double-Blind, Multi-Center Study in Adult Subjects With Eosinophilic Esophagitis (EoE) to Evaluate the Safety and Efficacy of Vonoprazan 20 mg Compared to Placebo After 12 Weeks and to Evaluate the Safety and Efficacy of Vonoprazan 20 mg Up to 24 Weeks
Primary endpoint: Number of Participants at Week 12 Achieving Peak Esophageal Intraepithelial Eosinophil Count <15 eos/hpf.
Vonoprazan Pregnancy Registry: An Observational Study of the Safety of Vonoprazan Exposure in Pregnant Women and Their Offspring
Primary endpoint: Number of Participants with Major Congenital Malformations (MCMs)
A Phase 1, Open-Label, Randomized, Single-Dose, 5-Period Crossover Study to Determine the Bioavailability of Two Vonoprazan Orally Disintegrating Tablet Formulations Administered Without Water or Mixed With Water and Administered Via a Syringe Relative to the Vonoprazan Tablet in Healthy Subjects
Primary endpoint: Maximum Observed Drug Concentration (Cmax) of Vonoprazan
A Phase 1, Open-label Study to Evaluate Vonoprazan Concentrations in Breast Milk of Healthy Lactating Women Receiving Vonoprazan 20 mg Once Daily or Vonoprazan 20 mg Twice Daily
Primary endpoint: Area Under Drug Concentration-time Curve From Time 0 to 24 Hours (AUC0-24) Following the Morning Dose of Vonoprazan in Breast Milk
14-day Banxiaxiexin Decoction Combined With Vonoprazan-Amoxicillin Dual Therapy in the Treatment of Helicobacter Pylori Infection Complicated With Functional Dyspepsia:A Single-Center,Randomized Controlled Study
Primary endpoint: Helicobacter pylori eradication rate
A Phase 1, Randomized, Parallel-group, Open-label, Multicenter Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of Vonoprazan (10 or 20 mg Once Daily) in Adolescents With Symptomatic Gastroesophageal Reflux Disease
Primary endpoint: Maximum Observed Drug Concentration at Steady State (Cmax-ss) of Vonoprazan
Special Drug Use Surveillance of Takecab Tablets for "Maintenance Therapy of Reflux Esophagitis: Long-term Use"
Primary endpoint: Percentage of Participants Who Had One or More Adverse Drug Reactions
Frequently asked questions
Who is developing vonoprazan?
vonoprazan is being developed by Phathom Pharmaceuticals, Inc..
How many clinical trials involve vonoprazan?
BioSniper tracks 8 clinical trials involving vonoprazan.